Table 1.

Factors associated with death in a cohort of HIV-infected patients in French Guiana 19922008: multivariate Cox modeling

	Time at risk (person-years)	Incidence rate	Adjusted hazard ratio	95% confidence interval	P
Age < 30 years	1797	2.28	1
Age [30-40 years]	2998	4.16	1.69	1.10-2.59	0.01
Age [40-60 years]	4116	3.76	1. 47	1.14-2.64	0.009
Age > 60	696	7	6.16	3.70-10.27	0.000
1991-1996 time-period	773	14.6	5.29	3.56-7.87	0.000
1997-2002 time-period	4182	4.47	2.68	1.96-3.68	0.000
2003-2008 time-period	4652	1.5	1
CD8 < first quartile (643/mm3)	2156	7.2	1.77	1.37-2.28	0.000
CD8 >=643 per mm3	6716	2.09
CD4 < 50	645	23.25	36.02	15.41-84.20	0.000
CD4 [50-200]	1809	5.14	12.34	5.32-28.63	0.000
CD4 [200-500]	4387	1.18	4.33	1.86-10.11	0.001
CD4 > 500	2167	0.27	1
Antiretroviral treatment	4938	1.47	.30	0.22-0.40	0.000
No antiretroviral treatment	4670	6.35
Tuberculosis (any location)	62	36.69	5.37	2.29-12.58	0.000
No tuberculosis	9546	3.63
Tuberculosis treatment	238	24.3	2.44	1.65-3.60	0.000
No tuberculosis treatment	9370	3.32
Interaction confirmed tuberculosis and tuberculosis treatment			0.20	0.07-0.60	0.004
Histoplasmosis	105	35.89	1.97	1.19-3.26	0.008
No histoplasmosis	9502	3.49
Histoplasmosis treatment	289	7.2	.79	0.37-1.57	0.50
No histoplasmosis treatment	9319	3.74
Interaction confirmed histoplasmosis and antifungal treatment			1.09	0.37-3.15	0.86
Pneumocystosis	70	17.06	4.18	1.48-11.80	0.007
No pneumocystosis	9538	3.75
Cotrimoxazole	2230	6.77	1.44	1.08-193	0.01
No cotrimoxazole	7378	2.96
Interaction pneumocystosis cotrimoxazole			0.13	0.03-0.49	0.003
Toxoplasmosis	86	44.14	3.52	1.97-6.28	0.000
No toxoplasmosis	9522	3.48